However, BRCA1/2 mutation-associated breast tumors display a great variability in immunogenicity with approximately 50% of tumors displaying an absent or mild tumor lymphocyte infiltrate and moderate neoantigen load, suggesting that only a subset of BRCA1/2 breast tumors may benefit from immune-based therapy (37). The gene discussed is BRCA1; the disease is neoplasm.